Peer-reviewed veterinary case report
Enoxaparin treatment and bleeding risks in dogs with immune anemia
By Panek, Cynthia M et al.·Published in Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)·2015·Advanced Veterinary Care Center·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Use of enoxaparin in dogs with primary immune-mediated hemolytic anemia: 21 cases.
- Species:
- dog
Plain-English summary
A group of 21 dogs with primary immune-mediated hemolytic anemia (IMHA), a condition where the immune system attacks red blood cells, was treated with enoxaparin, a blood thinner. The dogs received this medication every six hours while hospitalized. Only two dogs experienced minor bleeding issues, and the overall survival rates were similar to those seen with other blood-thinning treatments for this condition. While enoxaparin appeared to be safe for these dogs, it’s still unclear if it offers any advantages over other treatments in preventing serious complications or improving survival.
People also search for: dog IMHA treatment · enoxaparin for dogs · immune-mediated hemolytic anemia in dogs
Abstract
OBJECTIVE: To describe the complications and frequency of thrombosis associated with the use of enoxaparin, a low molecular weight heparin, in dogs with primary immune-mediated hemolytic anemia (IMHA). DESIGN: Retrospective case series. SETTING: Two privately owned veterinary referral hospitals. ANIMALS: Twenty-one client-owned dogs with primary IMHA. INTERVENTIONS: Dogs were treated with enoxaparin (0.8 mg/kg subcutaneously every 6 h) as the sole anticoagulation therapy starting at admission to the hospital. MEASUREMENTS AND MAIN RESULTS: Only 2 dogs had minor hemorrhagic complications associated with enoxaparin therapy. Frequency of thrombosis was not assessed. Long-term survival was comparable to other anticoagulation protocols reported for dogs with primary IMHA. CONCLUSIONS: The use of enoxaparin was safe in a small group of dogs with primary IMHA. Whether enoxaparin therapy can reduce mortality and thrombotic complications in dogs with primary IMHA compared with other anticoagulation protocols remains unknown.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25773906/